Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $30 | 7-10 days | |
10 mg | $44 | 7-10 days | |
1 mL x 10 mM (in DMSO) | $43 | 7-10 days |
Description | Teneligliptin (MP-513) is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. Teneligliptin (MP-513) inhibits all these DPP-4 enzymes in a concentration-dependent manner. The IC50s of Teneligliptin (MP-513) for rhDPP-4, human plasma, and rat plasma are 0.889, 1.75, and 1.35 nM, respectively. A study of enzyme inhibition kinetics is conducted for Teneligliptin (MP-513) using Gly-Pro-MCA as the substrate and rhDPP-4 as the enzyme source. Plots based on the Michaelis-Menten equation reveals that Teneligliptin (MP-513) inhibits DPP-4 in a substrate-competitivemanner; the residual sum of squares for competitive and non-competitive models is 0.162 and 0.192, respectively. Ki, Km, and Vmax values are 0.406 nM, 24 μM, and 6.06 nmol/min, respectively. Teneligliptin (MP-513) inhibits the degradation of GLP-1(7-36)amide with an IC50 of 2.92 nM[1]. Oral administration of Teneligliptin (MP-513) in Wistar rats results in the inhibition of plasma DPP-4 with an ED50 of 0.41 mg/kg. Plasma DPP-4 inhibition is sustained even at 24 h after administration of Teneligliptin (MP-513). An oral carbohydrate-loading test in Zucker fatty rats shows that Teneligliptin (MP-513) at ≥0.1 mg/kg increases the maximum increase in plasmaglucagon-like peptide-1 and insulin levels, and reduces glucose excursions. This effect is observed over 12 h after a dose of 1 mg/kg. An oral fat-loading test in Zucker fatty rats also shows that Teneligliptin (MP-513) at 1 mg/kg reduces triglyceride and free fatty acid excursions. In Zucker fatty rats, repeated administration of Teneligliptin (MP-513) for two weeks reduces glucose excursions in the oral carbohydrate-loading test and decreased the plasma levels of triglycerides and free fatty acids under non-fasting conditions. Oral administration of Teneligliptin (MP-513) inhibits plasma DPP-4 in rats in a dose-dependent manner. The ED50 value for Teneligliptin (MP-513) is calculated to be 0.41 mg/kg, while those for Sitagliptin and Vildagliptin, 27.3 and 12.8 mg/kg, respectively[1]. Teneligliptin (MP-513) improves the histopathological appearance of the liver and decreases intrahepatic triglyceride levels in an NAFLD model mouse, which is associated with downregulation of hepatic lipogenesis-related genes due to AMPK activation[2]. [1]. Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. [2]. Ideta T, et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015 Dec 8;16(12):29207-18. |
In vitro | Teneligliptin (MP-513) demonstrates concentration-dependent inhibition of DPP-4 enzymes across various contexts, with IC50 values of 0.889 nM for rhDPP-4, 1.75 nM for human plasma, and 1.35 nM for rat plasma. Enzyme inhibition kinetics, analyzed using Gly-Pro-MCA substrate and rhDPP-4, show Teneligliptin acts via a substrate-competitive mechanism. This is supported by residual sum of squares analyses, yielding 0.162 for competitive and 0.192 for non-competitive models, alongside calculated Ki, Km, and Vmax values of 0.406 nM, 24 μM, and 6.06 nmol/min, respectively. Furthermore, Teneligliptin effectively protects GLP-1(7-36)amide from degradation, evidenced by an IC50 of 2.92 nM. |
In vivo | Oral administration of Teneligliptin (MP-513) to Wistar rats significantly inhibits plasma DPP-4 activity, achieving an ED50 of 0.41 mg/kg and maintaining this inhibition for 24 hours post-dose. When administered to Zucker fatty rats, Teneligliptin at doses of 0.1 mg/kg or higher enhances plasmaglucagon-like peptide-1 and insulin levels, curtails glucose levels during oral carbohydrate challenges up to 12 hours after a 1 mg/kg dose, and reduces triglyceride and free fatty acid levels after oral fat challenges. Continuous dosing over two weeks similarly decreases blood glucose, triglycerides, and free fatty acids under non-fasting conditions. Compared to Sitagliptin and Vildagliptin, with ED50 values of 27.3 and 12.8 mg/kg respectively, Teneligliptin shows a markedly higher potency in dose-dependent plasma DPP-4 inhibition. Additionally, Teneligliptin improves liver histopathology and reduces intrahepatic triglyceride levels in NAFLD model mice by downregulating genes involved in hepatic lipogenesis through AMPK activation. |
Kinase Assay | DPP-4 inhibition assay is carried out using either 5 ng purified recombinant human DPP-4 (rhDPP-4), human plasma (20-fold diluted with assay buffer; phosphate-buffered saline (PBS) containing 0.003% Brij-35 solution), or rat plasma (10-fold diluted with assay buffer) Gly-Pro-MCA as a chromogenic substrate as described previously with slight modifications. DPP-4 inhibitors (Teneligliptin, Sitagliptin, and Vildagliptin) are diluted with assay buffer at several concentrations. Twenty microliters of inhibitor solution, 20 μL of the enzyme source, and 20 μL of Gly-Pro-MCA (final concentration, 25 μM) are mixed with 140 μL or 160 μL of assay buffer to initiate the enzyme reaction. After 20 min (rhDPP-4) or 1 h (plasma) at 37°C, the fluorescence intensity of 7-amino-4-methyl-coumarin (AMC) generated from Gly-Pro-MCA is measured using an automated microplate reader at 360 nm excitation and 465 nm emission. The fluorescence intensity of AMC corresponded to DPP-4 activity[1]. |
Molecular Weight | 426.58 |
Formula | C22H30N6OS |
Cas No. | 760937-92-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 33.33 mg/mL (78.13 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.